Effect of Empagliflozin on cardiomyopathy induced chemotherapy

Evaloation the effect of empagliflozin on cardiomyopathy induecd chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240126060818N1

Enrollment

Registered

2025-05-28

Start date

2024-03-05

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: cardiomyopathy. Condition 2: cardiomyopathy induced cgemotherapy. Cardiomyopathy Cardiomyopathy due to drug and external agent

Interventions

Intervention 1: Intervention group: Daily intake of one empagliflozin 10 mg tablet from the day before starting chemotherapy until 90 days later. Intervention 2: Control group: aily use of a placebo f

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients to start chemotherapy with drugs with potential cardiomyopathy effect

Exclusion criteria

Exclusion criteria: The patient's lack of consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Ejection fraction (EF). Timepoint: day 0 and 90. Method of measurement: ecocardiography.;ProBNP Lab Test. Timepoint: Day 0 and 90. Method of measurement: Lab.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Amini

Artesh University of Medical Sciences

Hosseinamini111@yahoo.com+98 21 6691 5942

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026